Aptahem AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APTA.ST research report →
Companywww.aptahem.com
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network.
- CEO
- Mikael Lindstam
- IPO
- 2015
- Employees
- 4
- HQ
- Malmö, SE
Price Chart
Valuation
- Market Cap
- $11.03M
- P/E
- -2.08
- P/S
- 7.86
- P/B
- 0.20
- EV/EBITDA
- -1.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.95%
- Op Margin
- -459.90%
- Net Margin
- -459.90%
- ROE
- -9.72%
- ROIC
- -9.58%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-6,490,000 · 24.26%
- EPS
- $-0.31 · 55.07%
- Op Income
- $-6,490,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $2.40
- 52W Low
- $0.50
- 50D MA
- $0.72
- 200D MA
- $1.04
- Beta
- 0.51
- Avg Volume
- 38.42K
Get TickerSpark's AI analysis on APTA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our APTA.ST Coverage
We haven't published any research on APTA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APTA.ST Report →